Feature | April 02, 2012

Small Change Makes Big Difference in Compliance Rates for Follow-Up Stress Tests

Scheduling Appointments Before Patients Leave ER Doubles Likelihood of Returning for Stress Test

April 2, 2012 — Stress tests are an important tool to help diagnose narrowed arteries in people who come to the emergency room (ER) with chest pain but are not confirmed as having a heart attack. Scheduling a follow-up exercise stress test before patients leave the ER more than doubles their likelihood of following through with the test, according to research presented at the American College of Cardiology (ACC) 61st Annual Scientific Session in Chicago.

The study, conducted in Australia, showed that among patients who were given an appointment for an exercise stress test before they left the ER, 70 percent actually underwent the test, compared with 31 percent of patients who were instructed to make the appointment themselves. Patients who were asked to make their own appointments also waited longer to take the test than those with pre-scheduled appointments (median time of 316 vs. just 77 hours, respectively).

“When patients were given a referral but were asked to make their own appointment, they often did not return for the stress test, despite the extra information the stress test can provide,” said Kevin Chung, M.D., University of Notre Dame in Fremantle, Australia, and the study’s lead investigator. “Our recommendation is that patients be given an appointment time for their test before they leave the ER. It’s even better to have the test before they leave the hospital.”

Exercise stress tests are one of several tools used to evaluate whether a person’s arteries are constricted by fatty build-up, which can increase the risk for a heart attack and other problems. The test monitors the electrical activity of the heart during exercise. Doctors use this information to decide whether a patient should be treated to reduce their risk of heart problems; failing to take the test puts patients at a higher risk of having an undiagnosed heart problem and not getting timely, appropriate care.

“In the ideal world, every patient who comes to the ER with chest pain would undergo a definitive test that gives 100 percent certainty of whether or not their arteries are normal,” Chung said. “While stress testing is not perfect, it provides very useful information. Any protocol that increases the proportion of patients having a stress test would help in patient follow-up.”

Previous studies have shown that patients who go to the ER with chest pain but are not confirmed as having a heart attack face a 2 to 3 percent chance of having a heart attack or other complication within 30 days. Current recommendations suggest these “intermediate risk” patients should undergo a stress test within 72 hours after discharge from the hospital.

The study also showed that patients with a clear understanding of the reason they were being asked to do an exercise stress test were more likely to attend their appointment. “From this we postulate that patient education regarding the rationale for the test will further improve compliance,” said Chung.

The researchers compared follow-up rates among 96 patients who were given an appointment for an exercise stress test before leaving the hospital with 121 patients who were asked to schedule their own appointments.

This study was self-funded by the University of Notre Dame in Fremantle, Australia; control group data were from a study funded by the Health Department of Western Australia.

For more information: www.acc.org.

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
News | Cardiac Diagnostics| September 12, 2017
Contracting shingles, a reactivation of the chickenpox virus, increases a person’s risk of stroke and heart attack,...
Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study in Denmark

Vascular screening for abdominal aortic aneurysm, peripheral artery disease and hypertension during the VIVA Study. Photo credit: Lisbeth Hasager Justesen, Viborg Hospital.

News | Cardiac Diagnostics| September 12, 2017
September 12, 2017 — A new screening program for vascular disease saves one life for every 169 men assessed, accordin
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Overlay Init